Biotech Values

[DewDiligence]

A prosecuting litigator would love those admissions from a party in the anti-trust case.

Indeed they would, but Rick Shea’s implicit message for SNY on a webcast that’s nominally intended for investors does not constitute an actionable antitrust offense.

All told, I think the way NVS/MNTA has formed a tacit agreement with SNY to avert the launch of a Lovenox authorized generic is pretty smart and is worthy of a case study in a law school’s curriculum.